<DOC>
	<DOCNO>NCT00161304</DOCNO>
	<brief_summary>The T-001 study placebo-controlled investigation effect injectable testosterone replacement therapy prostate tissue age men low testosterone level . The primary objective study measure change tissue hormone biomarkers prostate tissue specimen .</brief_summary>
	<brief_title>Study Determine Effects Testosterone Replacement Therapy Aging Men With Androgen Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria 1 . Male aged 5080 year age , ambulatory , good general physical mental health . 2 . Clinical diagnosis hypogonadism define serum testosterone level le 300 ng/dl morning serum sample screen period . 3 . Answering yes question 1 7 three question total Morley index baseline . 4 . PSA &lt; 10 ng/ml 5 . Subject able give inform consent . Exclusion Criteria 1 . Failure meet criterion inclusion 2 . History allergy testosterone component delivery system . 3 . Significant abnormality prestudy clinical examination laboratory measurement . 4 . Treatment investigational drug previous month . 5 . Drug alcohol abuse dependence . 6 . Concurrent use testosterone hormonal therapy , include health food supplement herbal product , could alter serum testosterone level affect prostate ( e.g . gonadotropic release hormone agonist , testosterone antagonist , anabolic steroid , DHEA , androstenedione , PCSPES , chrysin tribulus terrestris , ) . Use alphareductase inhibitor prostate phytotherapy within past 3 month . 7 . Use antidepressant medication , oral glucocorticoid , opioids . 8 . PSA &gt; 10 ng/ml and/or prostate biopsy positive cancer screen . Any patient suspicion prostate cancer must undergo appropriate testing rule cancer prior entry study . 9 . IPSS score ï‚³ 20 . 10 . History malignancy type ( except basal cell carcinoma ) . 11 . Patients uncontrolled diabetes . 12 . Patients know suspected bleeding disorder . Concurrent use Coumadin anticoagulant time biopsy discontinuation therapy prior biopsy pose risk patient . 13 . Inability patient provide write informed consent reason , include legal incompetence , language comprehension difficulty , psychological , psychiatric emotional factor . 14 . Inability patient transrectal ultrasonography biopsy ( reason ) . 15 . A history illness condition , opinion investigator , might confound result study pose additional risk patient .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
</DOC>